Roche, Biogen handing over $470M in cash to bag two drug programs from Bristol-Myers Squibb
Bristol-Myers Squibb has forged a pair of separate pacts with Roche and Biogen to outlicense two drugs, grabbing a whopping $470 million upfront for the deals.
Biogen gets control of BMS-986168, an anti-eTau compound in clinical development for Progressive Supranuclear Palsy, for $300 million upfront and $410 million in milestones. And Roche gets BMS-986089, an anti-myostatin Adnectin in development for Duchenne muscular dystrophy. Roche is paying $170 million plus $205 million in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.